Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Gains from Investment Securities: 2023-2025

Historic Gains from Investment Securities for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to $300,000.

  • Immunome's Gains from Investment Securities fell 86.36% to $300,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year change of. This contributed to the annual value of $6.6 million for FY2024, which is 17.07% down from last year.
  • Latest data reveals that Immunome reported Gains from Investment Securities of $300,000 as of Q3 2025, which was up 200.00% from $100,000 recorded in Q2 2025.
  • In the past 5 years, Immunome's Gains from Investment Securities registered a high of $8.5 million during Q1 2024, and its lowest value of $100,000 during Q2 2025.
  • Moreover, its 3-year median value for Gains from Investment Securities was $2.5 million (2023), whereas its average is $2.9 million.
  • In the last 5 years, Immunome's Gains from Investment Securities skyrocketed by 242.17% in 2024 and then crashed by 97.06% in 2025.
  • Immunome's Gains from Investment Securities (Quarterly) stood at $5.8 million in 2023, then slumped by 62.07% to $2.2 million in 2024, then tumbled by 86.36% to $300,000 in 2025.
  • Its last three reported values are $300,000 in Q3 2025, $100,000 for Q2 2025, and $348,748 during Q1 2025.